Drug Topics

JULY 5, 2023

How does AI help reduce the burden on specialist dermatology services and help simplify the screening process?

180

180

Fierce Pharma

JULY 6, 2023

After becoming chairman of the powerful Senate Health, Education, Labor and Pensions Committee earlier this year, Sen. | After becoming chairman of the powerful Senate Health, Education, Labor and Pensions Committee earlier this year, Sen. Bernie Sanders, I-Vermont—a longtime opponent of Big Pharma—has become even more ubiquitous in his efforts to reduce drug prices.

145

145

Pharmacy Times

JULY 6, 2023

The benefits of the survey can stretch beyond assessing the parental acceptability of mental health screenings in children and can suggest areas of optimization in providing these screenings more widely and effectively in the future.

132

132

STAT

JULY 7, 2023

Jonathan Studnek knows some people imagine that driving an ambulance at high speed with lights flashing and sirens wailing — racing through messily parted traffic to the scene of a crisis — is the best part of being an emergency medic. For him, that couldn’t be further from the truth. “If you’ve been in the industry for any length, you know innately: When you’re in the front of an ambulance and the lights are on, that’s the most dangerous situatio

Hospitals 123

Hospitals 123

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Fierce Healthcare

JULY 5, 2023

“Digital health will cease to exist,” read large on the screen behind Merck Global Health Initiative Fund President Bill Taranto at the second annual HITLAB Innovators Summit in New York City. | Columbia University hosted the second annual HITLAB Innovators Summit in New York City where industry insiders trumpeted the potential for digital health interventions while warning of the dangers of unchecked tech implementation.

114

114

Fierce Pharma

JULY 6, 2023

Less than two months into its "Pivot to Growth" strategy under a new CEO, Israeli-American generics giant Teva Pharmaceutical could be weighing a major shake-up of its key drug ingredients business | Teva is looking at strategic options for its active pharmaceutical ingredient unit, with a potential sale on the table, BNN Bloomberg and Benzinga have reported.

143

143

STAT

JULY 3, 2023

When the U.S. Supreme Court released its landmark ruling overturning the use of race-conscious college admissions, LaShyra Nolen was on clinical rotation. For Nolen, a fourth-year medical student at Harvard Medical School, the news sent a chill down her spine even though she had been anticipating it. “It felt very lonely,” said Nolen, who is Black and the first in her family to get a bachelors of science degree and attend medical school.

Medical Schools 114

Medical Schools 114

Fierce Healthcare

JULY 7, 2023

Air pollution shown to increase depression symptoms in individuals with bipolar disorder, a new study published by Cambridge University Press found.

124

124

Fierce Pharma

JULY 7, 2023

As demand skyrockets for GLP-1 drugs that can trigger significant weight loss, unauthorized versions of the treatments have started to fill pharmacies. | In late May, the FDA warned of illegal knockoffs of Novo Nordisk’s Ozempic and Wegovy. And now, the Danish company has filed its second wave of lawsuits against pharmacies in the U.S. that are producing the copycats.

Compounding 129

Compounding FDA 129

Pharmacy Times

JULY 7, 2023

Diagnostic technologies are advancing quickly, which may lead to therapeutics for age-related diseases to safely reduce chronic low-grade inflammation generated by the immune system.

Immunization 123

Immunization 123

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

JULY 6, 2023

The STAT Diversity and Inclusion Committee is proud to present STAT’s inaugural Diversity and Inclusion Report. Here, we share the self-reported gender and racial/ethnic demographics of our staff from STAT’s inception in 2015 through 2022. This report presents an opportunity to reaffirm STAT’s commitment to becoming the most diverse media company covering the life sciences and health care.

110

110

Fierce Healthcare

JULY 6, 2023

Stanford Medicine and the Department of Veterans Affairs (VA) unveiled plans Friday to collaborate on a project that will bring a new National Cancer Institute-designated joint cancer care and rese | Stanford Medicine and the VA unveiled plans on Friday to collaborate on a project that will bring a new National Cancer Institute-designated joint cancer care and research center to the VA Palo Alto campus.

Department of Veterans Affairs 110

Department of Veterans Affairs 110

Fierce Pharma

JULY 5, 2023

Despite political tensions between Washington and Beijing, foreign pharmaceutical investments are progressing in China. | In a deal that could be worth up to $1 billion, Massachusetts-based Moderna inked a memorandum of understanding, plus a land collaboration agreement, to research, develop and manufacture mRNA medicines in China.

118

118

Pharmacy Times

JULY 5, 2023

Adam C. Welch, PharmD, MBA, FAPhA, and Chad Worz, PharmD BCGP, FASCP, discusse the development of recombinant and cell-based vaccines and the new types of flu vaccines being explored.

Vaccines 123

Vaccines 123

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

STAT

JULY 7, 2023

The recent FDA approval of Leqembi , the latest anti-amyloid drug, is undoubtedly a breakthrough for the field, providing a new way to slow the advancement of mild cognitive impairment or early-stage Alzheimer’s disease. As a practicing geriatrician who has treated Alzheimer’s patients for more than 40 years and the co-founder and chief science officer at the Alzheimer’s Drug Discovery Foundation, I have never been more optimistic about our potential to transform how we trea

FDA 107

FDA 107

Fierce Healthcare

JULY 5, 2023

Hospital outpatient departments are marking up the prices for biologic medicines more than physician offices, particularly for “innovator biologics” that have clinically equivalent and lower cost a | Consistently higher markups among hospital outpatient departments hamstring potential savings payers may hope to see down the line as more biosimilars become available, warned the Employee Benefit Research Institute.

Hospitals 110

Hospitals 110

Fierce Pharma

JULY 6, 2023

It’s official: Roughly half a year after the FDA granted an accelerated nod to Eisai and Biogen’s new Alzheimer’s disease med lecanemab, the companies have converted that green light into a full-fl | With a full approval in hand, Leqembi has become the first treatment shown to reduce the rate of disease progression and slow cognitive and functional decline in adults with Alzheimer’s disease under the FDA's traditional approval pathway.

FDA 115

FDA 115

Pharmacy Times

JULY 3, 2023

All individuals with type 1 diabetes on the therapy had restored insulin secretion, improved glycemic control, improved time-in-range reduction, or elimination of exogenous insulin usage.

123

123

Pharmaceutical Technology

JULY 4, 2023

Substance use disorders leave people with long-term negative mental and physical health implications and can lead to death.

130

130

Fierce Healthcare

JULY 5, 2023

The quality bonus program (QBP) that rewards Medicare Advantage (MA) plans fails to achieve its two main goals: fairly rewarding MA insurers that actually improve quality and encouraging beneficiar | The Medicare Advantage Quality Bonus Program suffers from what some experts call the “Lake Wobegon Effect”: Too many plans are rated above average. A new Urban Institute report suggests some cures.

Insurance 110

Insurance 110

Fierce Pharma

JULY 6, 2023

GSK’s Cabenuva made history in 2020 as the world’s firs | GSK's long-acting Cabenuva is currently approved only as a switch therapy for patients who already have undetectable HIV levels in the blood. Trying to reach some tough populations who have difficulty adhering to existing daily oral therapies, GSK is getting creative.

110

110

Pharmacy Times

JULY 3, 2023

Using data from a wide-ranging survey of Medicare enrollees, investigators found that using value weights from participants would have a negative impact on smaller, rural hospitals.

Hospitals 123

Hospitals 123

PharmExec

JULY 5, 2023

Rose Blackburne, MD, MBA, vice president, global head, general medicine, PPD Clinical Research, Thermo Fisher Scientific, discusses health equity in pharma, specifically racial biases, and how the industry can address inequities in access and care going forward.

105

105

STAT

JULY 5, 2023

WASHINGTON – Novo Nordisk spent $11 million on meals and travel for thousands of doctors last year, federal records show, as part of its push to promote Ozempic and other weight loss-inducing diabetes drugs. The pharmaceutical company bought more than 457,000 meals to educate doctors and other prescribers about its portfolio of drugs known as GLP-1 agonists, according to the newly released data from the Centers for Medicare and Medicaid Services.

Pharmaceutical Companies 105

Pharmaceutical Companies Pharmaceutical Companies 105

Fierce Pharma

JULY 7, 2023

AstraZeneca and Daiichi Sankyo's TROP2 antibody-drug conjugate returned a concerning safety message. Moderna reportedly plans to invest up to $1 billion in China. | AstraZeneca and Daiichi Sankyo delivered a concerning safety message for their TROP2 antibody-drug conjugate. Moderna reportedly plans to invest up to $1 billion in China. Takeda expanded its antibody partnership with F-Star Therapeutics with a new deal potentially worth $1 billion.

105

105

Pharmacy Times

JULY 6, 2023

Lecanemab-irmb is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer disease.

FDA 123

FDA 123

Fierce Healthcare

JULY 5, 2023

Healthcare mergers and acquisitions are in no short supply as providers, health tech companies, payers and other industry players look to expand their businesses and gain a competitive edge. | Bright Health exits insurance business, Vandalia Health to add three hospitals, Centene divests AI platform and more M&A news from the month of June.

Insurance 105

Insurance Hospitals 105

Pharmaceutical Technology

JULY 3, 2023

Pipeline developments within the obesity space have recently garnered interest following recent results published on Eli Lilly’s retatrutide.

119

119

Fierce Pharma

JULY 5, 2023

While the price of just about everything has increased over the last six years in the U.S., the same can’t be said for the cost of an FDA priority review voucher. Just ask Sarepta Therapeutics. | The price of priority review vouchers is falling. Just ask Sarepta Therapeutics. Since 2017, the company has sold off three PRVs—getting less in return for each successive sale.

FDA 105

FDA 105

Pharmacy Times

JULY 3, 2023

The study also found significant evidence of outcomes disparities between minority populations and White populations.

149

149

Outsourcing Pharma

JULY 5, 2023

Lucy Jung is the CEO and founder at Charco Neurotech, a medtech start-up which has developed the CEU1, a non-invasive wearable device for Parkinson's, that uses vibrotactile stimulation to reduce symptoms of slowness and stiffness resulting in improved movement. We spoke to her about her background, how she got involved in the Parkinson's space and her fascination for problem-solving.

104

104

STAT

JULY 6, 2023

When then-Vice President Biden launched the Cancer Moonshot in 2016, there was reason to be optimistic. Decades of rigorous science had transformed many cancers from a death sentence to a manageable chronic disease. New treatment advances — including gene and cell therapies and immunotherapies — were showing stunning results. With support from the biopharmaceutical industry and the help of smart government policies, ending cancer was, and is, an achievable goal.

103

103

Fierce Pharma

JULY 6, 2023

During the first earnings call Brent Saunders led since his return at Bausch + Lomb, the CEO laid out what he believes is the company’s biggest issue: underutilization of existing infrastructure. | During the first earnings call Brent Saunders led since his return at Bausch + Lomb, the CEO laid out what he believes is the company’s biggest issue: underutilization of existing infrastructure.

105

105

Pharmacy Times

JULY 5, 2023

An expert panel discussed the outreach of social determinants of health in community pharmacy care and how pharmacists can help patients find and access resources.

Community Pharmacies 123

Community Pharmacies 123